Back to CITADEL ADVISORS LLC CITADEL ADVISORS LLC

TAKTAK
30 quarters

Position history for CITADEL ADVISORS LLCCITADEL ADVISORS LLC's holdings in TAKEDA PHARMACEUTICAL CO LTD

CITADEL ADVISORS LLC holds 624,160 shares of TAK (TAKEDA PHARMACEUTICAL CO LTD), worth $11.6M as of 2026-Q1. The position was increased (+60.1% shares). TAK represents 0.0% of CITADEL ADVISORS LLC's portfolio.

Current Value

$11.6M

Current Shares

624,160

Total Value Change

+$1.9M

Total Shares Change

+47,076

Quarter-by-Quarter History
QuarterActionSharesChangeValueWeightPriceConviction
2026-Q1
Latest
Increased
624,160
+60.1%
$11.6M0.0%$18.08
40
2025-Q4
Increased
389,734
+415.4%
$6.1M0.0%$15.63
44
2025-Q3
New
75,624
-
$1.1M0.0%$14.62
35
2025-Q2
Exited
0
-100.0%
$00.0%$15.10
0
2025-Q1
Increased
142,556
+275.3%
$2.1M0.0%$14.71
42
2024-Q4
New
37,989
-
$502,9740.0%$12.87
33
2024-Q3
Exited
0
-100.0%
$00.0%$13.89
0
2024-Q2
Increased
312,081
+3294.0%
$4M0.0%$12.36
43
2024-Q1
Decreased
9,195
-90.4%
$127,7190.0%$13.27
0
2023-Q4
Increased
95,759
+2494.4%
$1.4M0.0%$13.36
41
2023-Q3
Decreased
3,691
-92.3%
$57,1000.0%$14.48
0
2023-Q2
Decreased
48,275
-13.8%
$758,4000.0%$14.70
0
2023-Q1
Increased
56,016
+183.7%
$923,1440.0%$15.31
40
2022-Q4
Decreased
19,743
-97.2%
$307,9910.0%$14.60
0
2022-Q3
Increased
697,825
+73.7%
$9.1M0.0%$12.14
41
2022-Q2
Increased
401,766
+16.9%
$5.6M0.0%$12.97
31
2022-Q1
Decreased
343,683
-5.1%
$4.9M0.0%$13.51
0
2021-Q4
Decreased
362,018
-9.5%
$4.9M0.0%$12.71
0
2021-Q3
Increased
399,978
+23.6%
$6.6M0.0%$15.27
33
2021-Q2
Increased
323,690
+51.8%
$5.4M0.0%$15.76
38
2021-Q1
Decreased
213,278
-39.6%
$3.9M0.0%$17.18
0
2020-Q4
Increased
353,400
+189.7%
$6.4M0.0%$17.02
44
2020-Q3
Increased
121,997
+14.4%
$2.2M0.0%$16.98
30
2020-Q2
Decreased
106,603
-48.0%
$1.9M0.0%$16.95
0
2020-Q1
Increased
205,037
+111.6%
$3.1M0.0%$14.63
43
2019-Q4
Decreased
96,883
-50.3%
$1.9M0.0%$18.41
0
2019-Q3
Increased
195,094
+15.2%
$3.4M0.0%$16.23
30
2019-Q2
Increased
169,306
+250.7%
$3M0.0%$16.57
43
2019-Q1
Decreased
48,278
-91.6%
$983,0000.0%$19.07
0
2018-Q4
New
577,084
-
$9.7M0.0%$15.67
38

Other major holders of TAK: GLENVIEW CAPITAL MANAGEMENT, LLC, Capital Research Global Investors

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used